Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 8Breast Neoplasms 8Lung Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Hematologic Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Rectal Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3COVID-19 3Uterine Cervical Neoplasms 2Smoking 2Sarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Head and Neck Neoplasms 2Head and Neck Carcinoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Breast Carcinoma In Situ 2Xerostomia 1Urologic Neoplasms 1Urologic Diseases 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bilateral Breast Carcinoma × Standard of Care × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡